IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis

• Published in: Experimental hematology & oncology Vol. 10; no. 1; pp. 58 - 4
• Main Authors: Cumbo, Cosimo, Tarantini, Francesco, Anelli, Luisa, Zagaria, Antonella, Redavid, Immacolata, Minervini, Crescenzio Francesco, Coccaro, Nicoletta, Tota, Giuseppina, Ricco, Alessandra, Parciante, Elisa, Conserva, Maria Rosa, Specchia, Giorgina, Musto, Pellegrino, Albano, Francesco
• Format: Journal Article
• Language: English
• Published: London BioMed Central 24.12.2021; BioMed Central Ltd; BMC
• Subjects: Biological response modifiers; Bone marrow; Cancer Research; Hematology; Interferon; IRF4 expression; Letter to the Editor; Leukemia; Medical prognosis; Medicine; Medicine & Public Health; Mutation; Oncology; Philadelphia negative MPNs; Prognosis; Tumors; Pennsylvania; Philadelphia negative MPNs; expression; Prognosis; IRF4 expression
• ISSN: 2162-3619; 2162-3619
• DOI: 10.1186/s40164-021-00253-y

Interferon regulatory factor 4 ( IRF4 ) is involved in the pathogenesis of various hematologic malignancies. Its expression has been related to the negative regulation of myeloid-derived suppressor cells (MDSCs) and the polarization of anti-inflammatory M2 macrophages, thereby altering immunosurveillance and inflammatory mechanisms. An abnormal inflammatory status in the bone marrow microenvironment of myeloproliferative neoplasms (MPNs) has recently been demonstrated; moreover, in chronic myeloid leukemia a downregulated expression of IRF4 has been found. In this context, we evaluated the IRF4 expression in 119 newly diagnosed consecutive Philadelphia negative MPNs (Ph- MPNs), showing a low expression among the MPNs phenotypes with a more significant decrease in primary myelofibrosis patients. Lower IRF4 levels were associated with JAK2  + and triple negatives cases carrying the worst prognosis. Furthermore, the IRF4 levels were related to leukemic transformation and a shorter leukemia-free survival; moreover, the risk of myelofibrosis transformation in polycythemia vera and essential thrombocythemia patients was more frequent in cases with lower IRF4 levels. Overall, our study demonstrates an IRF4 dysregulated expression in MPNs patients and its association with a worse prognosis. Further studies could validate these data, to improve our knowledge of the MPNs pathogenesis and confirm the IRF4 role as a new prognostic factor.